{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:41:50Z","timestamp":1781052110627,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>\nAbstract\n<\/jats:title><jats:p>Endogenous Cushing\u2019s syndrome (CS) is associated with increased morbidity and mortality. Early diagnosis and initiation of therapy are essential, but effective treatment remains a challenge. In a long-term follow-up, biochemical control of hypercortisolemia, especially when severe, is difficult to achieve. Life-threatening hypercortisolemia is difficult to control due to the limitations of pharmacotherapy, including its side effects, and may require etomidate infusion in the intensive care unit (ICU) to rapidly lower cortisol levels. The effectiveness of hypercortisolemia management can be increased by a dual blockade of cortisol production. We report the efficacy, safety, and tolerability of combined therapy with two steroidogenesis inhibitors, etomidate, and osilodrostat, in a 32-year-old woman diagnosed with severe ACTH-dependent hypercortisolemia, subsequently maintaining a stable level of cortisol with osilodrostat monotherapy. This approach enabled achievement of relatively rapid control of the hypercortisolemia while using an etomidate infusion and concomitant increasing doses of oral osilodrostat applying a \u201ctitrations strategy.\u201d Our experience shows that it is worth taking advantage of the synergistic anticortisolic action of etomidate with osilodrostat.<\/jats:p>","DOI":"10.1007\/s42000-022-00397-4","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T06:06:20Z","timestamp":1663740380000},"page":"735-742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cushing\u2019s syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9283-4827","authenticated-orcid":false,"given":"Lukasz","family":"Dzialach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0440-2851","authenticated-orcid":false,"given":"Joanna","family":"Sobolewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioleta","family":"Respondek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-7752","authenticated-orcid":false,"given":"Agnieszka","family":"Wojciechowska-Luzniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4512-4624","authenticated-orcid":false,"given":"Przemyslaw","family":"Witek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"397_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing\u2019s syndrome. Lancet 386:913\u2013927. https:\/\/doi.org\/10.1016\/S0140-6736(14)61375-1","journal-title":"Lancet"},{"key":"397_CR2","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BMK, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A (2015) Treatment of Cushing\u2019s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100:2807\u20132831. https:\/\/doi.org\/10.1210\/jc.2015-1818","journal-title":"J Clin Endocrinol Metab"},{"key":"397_CR3","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1210\/jc.2012-3582","volume":"98","author":"OM Dekkers","year":"2013","unstructured":"Dekkers OM, Horv\u00e1th-Puh\u00f3 E, J\u00f8rgensen JOL, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, Pereira AM, S\u00f8rensen HT (2013) Multisystem morbidity and mortality in Cushing\u2019s syndrome: a cohort study. J Clin Endocrinol Metab 98:2277\u20132284. https:\/\/doi.org\/10.1210\/jc.2012-3582","journal-title":"J Clin Endocrinol Metab"},{"key":"397_CR4","doi-asserted-by":"publisher","first-page":"101380","DOI":"10.1016\/j.beem.2020.101380","volume":"34","author":"M Barbot","year":"2020","unstructured":"Barbot M, Zilio M, Scaroni C (2020) Cushing\u2019s syndrome: overview of clinical presentation, diagnostic tools and complications. Best Pract Res Clin Endocrinol Metab 34:101380. https:\/\/doi.org\/10.1016\/j.beem.2020.101380","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"397_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BMK, Colao A (2016) Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol 4:611\u2013629. https:\/\/doi.org\/10.1016\/S2213-8587(16)00086-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"397_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40265-016-0539-6","volume":"76","author":"KI Alexandraki","year":"2016","unstructured":"Alexandraki KI, Grossman AB (2016) Therapeutic strategies for the treatment of severe Cushing\u2019s syndrome. Drugs 76:447\u2013458. https:\/\/doi.org\/10.1007\/s40265-016-0539-6","journal-title":"Drugs"},{"key":"397_CR7","doi-asserted-by":"publisher","first-page":"204201881982554","DOI":"10.1177\/2042018819825541","volume":"10","author":"A \u0141ebek-Szata\u0144ska","year":"2019","unstructured":"\u0141ebek-Szata\u0144ska A, Nowak KM, Zgliczy\u0144ski W, Baum E, \u017by\u0142ka A, Papierska L (2019) Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature. Ther Adv Endocrinol Metab 10:204201881982554. https:\/\/doi.org\/10.1177\/2042018819825541","journal-title":"Ther Adv Endocrinol Metab"},{"key":"397_CR8","doi-asserted-by":"publisher","first-page":"101490","DOI":"10.1016\/j.beem.2021.101490","volume":"35","author":"EV Varlamov","year":"2021","unstructured":"Varlamov EV, Han AJ, Fleseriu M (2021) Updates in adrenal steroidogenesis inhibitors for Cushing\u2019s syndrome \u2013 a practical guide. Best Pract Res Clin Endocrinol Metab 35:101490. https:\/\/doi.org\/10.1016\/j.beem.2021.101490","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"397_CR9","doi-asserted-by":"publisher","first-page":"101381","DOI":"10.1016\/j.beem.2020.101381","volume":"34","author":"A Ferriere","year":"2020","unstructured":"Ferriere A, Tabarin A (2020) Cushing\u2019s syndrome: Treatment and new therapeutic approaches. Best Pract Res Clin Endocrinol Metab 34:101381. https:\/\/doi.org\/10.1016\/j.beem.2020.101381","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"397_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11102-016-0742-1","volume":"19","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Castinetti F (2016) Updates on the role of adrenal steroidogenesis inhibitors in Cushing\u2019s syndrome: a focus on novel therapies. Pituitary 19:643\u2013653. https:\/\/doi.org\/10.1007\/s11102-016-0742-1","journal-title":"Pituitary"},{"key":"397_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1530\/EJE-12-0274","volume":"167","author":"VA Preda","year":"2012","unstructured":"Preda VA, Sen J, Karavitaki N, Grossman AB (2012) Therapy in endocrine disease: etomidate in the management of hypercortisolaemia in Cushing\u2019s syndrome: a review. Eur J Endocrinol 167:137\u2013143. https:\/\/doi.org\/10.1530\/EJE-12-0274","journal-title":"Eur J Endocrinol"},{"key":"397_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/BF01735795","volume":"66","author":"B Allolio","year":"1988","unstructured":"Allolio B, Schulte HM, Kaulen D, Reincke M, Jaursch-Hancke C, Winkelmann W (1988) Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing\u2019s syndrome. Klin Wochenschr 66:361\u2013364. https:\/\/doi.org\/10.1007\/BF01735795","journal-title":"Klin Wochenschr"},{"key":"397_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/0039-128X(93)90054-Q","volume":"58","author":"I Varga","year":"1993","unstructured":"Varga I, R\u00e1cz K, Kiss R, F\u00fct\u00f6 L, T\u00f3th M, Sergev O, Gl\u00e1z E (1993) Direct inhibitory effect of etomidate on corticosteroid secretion in human pathologic adrenocortical cells. Steroids 58:64\u201368. https:\/\/doi.org\/10.1016\/0039-128X(93)90054-Q","journal-title":"Steroids"},{"key":"397_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11102-011-0314-3","volume":"15","author":"J Heyn","year":"2012","unstructured":"Heyn J, Geiger C, Hinske CL, Briegel J, Weis F (2012) Medical suppression of hypercortisolemia in Cushing\u2019s syndrome with particular consideration of etomidate. Pituitary 15:117\u2013125. https:\/\/doi.org\/10.1007\/s11102-011-0314-3","journal-title":"Pituitary"},{"key":"397_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40360-019-0328-4","volume":"20","author":"M McGrath","year":"2019","unstructured":"McGrath M, Hofmann A, Raines DE (2019) Behavioral and steroidogenic pharmacology of phenyl ring substituted etomidate analogs in rats. BMC Pharmacol Toxicol 20:48. https:\/\/doi.org\/10.1186\/s40360-019-0328-4","journal-title":"BMC Pharmacol Toxicol"},{"key":"397_CR16","doi-asserted-by":"publisher","first-page":"R121","DOI":"10.1186\/cc11415","volume":"16","author":"N Molenaar","year":"2012","unstructured":"Molenaar N, Bijkerk RM, Beishuizen A, Hempen CM, de Jong MF, Vermes I, van der Sluijs VG, Girbes AR, Groeneveld AJ (2012) Steroidogenesis in the adrenal dysfunction of critical illness: impact of etomidate. Crit Care 16:R121. https:\/\/doi.org\/10.1186\/cc11415","journal-title":"Crit Care"},{"key":"397_CR17","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1210\/jc.2013-2117","volume":"99","author":"X Bertagna","year":"2014","unstructured":"Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, Watson CE, Maldonado M, Hamrahian AH, Boscaro M, Biller BMK (2014) LCI699, a Potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 99:1375\u20131383. https:\/\/doi.org\/10.1210\/jc.2013-2117","journal-title":"J Clin Endocrinol Metab"},{"key":"397_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","volume":"19","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C, Tanaka T, Shimatsu A, White T, Hilliard A, Tian C, Sauter N, Biller BM, Bertagna X (2016) Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing\u2019s disease. Pituitary 19:138\u2013148. https:\/\/doi.org\/10.1007\/s11102-015-0692-z","journal-title":"Pituitary"},{"key":"397_CR19","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1210\/jc.2019-00217","volume":"104","author":"SG Creemers","year":"2019","unstructured":"Creemers SG, Feelders RA, de Jong FH, Franssen GJH, de Rijke YB, van Koetsveld PM, Hofland LJ (2019) Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: an in vitro study. J Clin Endocrinol Metab 104:3437\u20133449. https:\/\/doi.org\/10.1210\/jc.2019-00217","journal-title":"J Clin Endocrinol Metab"},{"key":"397_CR20","doi-asserted-by":"publisher","unstructured":"Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A, Witek P, Belaya Z, Yu Y, Liao Z, Ku CHC, Carvalho D, Roughton M, Wojna J, Pedroncelli AM, Snyder PJ (2022) Randomized trial of osilodrostat for the treatment of Cushing disease. J Clin Endocrinol Metab dgac178. https:\/\/doi.org\/10.1210\/clinem\/dgac178","DOI":"10.1210\/clinem\/dgac178"},{"key":"397_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.5603\/EP.a2022.0009","volume":"73","author":"P Witek","year":"2022","unstructured":"Witek P, Mehlich A, Stasiewicz A, Jawiarczyk-Przyby\u0142owska A, Bolanowski M (2022) Osilodrostat - an emerging drug for the medical management of Cushing\u2019s disease. Endokrynol Pol 73:371\u2013374. https:\/\/doi.org\/10.5603\/EP.a2022.0009","journal-title":"Endokrynol Pol"},{"key":"397_CR22","doi-asserted-by":"publisher","first-page":"L7","DOI":"10.1530\/EJE-20-0557","volume":"183","author":"M Haissaguerre","year":"2020","unstructured":"Haissaguerre M, Puerto M, Nunes M-L, Tabarin A (2020) Efficacy and tolerance of osilodrostat in patients with severe Cushing\u2019s syndrome due to non-pituitary cancers. Eur J Endocrinol 183:L7\u2013L9. https:\/\/doi.org\/10.1530\/EJE-20-0557","journal-title":"Eur J Endocrinol"},{"key":"397_CR23","doi-asserted-by":"publisher","first-page":"L13","DOI":"10.1530\/EJE-21-0147","volume":"184","author":"L Bessi\u00e8ne","year":"2021","unstructured":"Bessi\u00e8ne L, Bonnet F, Tenenbaum F, Jozwiak M, Corchia A, Bertherat J, Groussin L (2021) Rapid control of severe ectopic Cushing\u2019s syndrome by oral osilodrostat monotherapy. Eur J Endocrinol 184:L13\u2013L15. https:\/\/doi.org\/10.1530\/EJE-21-0147","journal-title":"Eur J Endocrinol"},{"key":"397_CR24","doi-asserted-by":"publisher","unstructured":"Amodru V, Brue T, Castinetti F (2021) Synergistic cortisol suppression by ketoconazole\u2013osilodrostat combination therapy. Endocrinol Diabetes Metab Case Rep 2021. https:\/\/doi.org\/10.1530\/EDM-21-0071","DOI":"10.1530\/EDM-21-0071"},{"key":"397_CR25","doi-asserted-by":"publisher","first-page":"962","DOI":"10.4158\/EP171787.OR","volume":"23","author":"EB Geer","year":"2017","unstructured":"Geer EB, Shafiq I, Gordon MB, Bonert V, Ayala A, Swerdloff RS, Katznelson L, Lalazar Y, Manuylova E, Pulaski-Liebert KJ, Carmichael JD, Hannoush Z, Surampudi V, Broder MS, Cherepanov D, Eagan M, Lee J, Said Q, Neary MP, Biller BMK (2017) Biochemical control during long-term follow-up of 230 adult patients with Cushing disease: a multicenter retrospective study. Endocr Pract 23:962\u2013970. https:\/\/doi.org\/10.4158\/EP171787.OR","journal-title":"Endocr Pract"},{"key":"397_CR26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1365-2265.2012.04424.x","volume":"77","author":"E Valassi","year":"2012","unstructured":"Valassi E, Crespo I, Gich I, Rodr\u00edguez J, Webb SM (2012) A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing\u2019s syndrome. Clin Endocrinol (Oxf) 77:735\u2013742. https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04424.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"397_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1530\/EJE-14-0913","volume":"172","author":"J-B Corcuff","year":"2015","unstructured":"Corcuff J-B, Young J, Masquefa-Giraud P, Chanson P, Baudin E, Tabarin A (2015) Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol 172:473\u2013481. https:\/\/doi.org\/10.1530\/EJE-14-0913","journal-title":"Eur J Endocrinol"},{"key":"397_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12020-017-1428-9","volume":"61","author":"M Claps","year":"2018","unstructured":"Claps M, Cerri S, Grisanti S, Lazzari B, Ferrari V, Roca E, Perotti P, Terzolo M, Sigala S, Berruti A (2018) Adding metyrapone to chemotherapy plus mitotane for Cushing\u2019s syndrome due to advanced adrenocortical carcinoma. Endocrine 61:169\u2013172. https:\/\/doi.org\/10.1007\/s12020-017-1428-9","journal-title":"Endocrine"},{"key":"397_CR29","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1210\/jc.2011-0536","volume":"96","author":"P Kamenick\u00fd","year":"2011","unstructured":"Kamenick\u00fd P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier J-F, Brailly-Tabard S, Leboulleux S, Schlumberger M, Baudin E, Chanson P, Young J (2011) Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome. J Clin Endocrinol Metab 96:2796\u20132804. https:\/\/doi.org\/10.1210\/jc.2011-0536","journal-title":"J Clin Endocrinol Metab"},{"key":"397_CR30","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, Caron P, Luca F, Donadille B, Vantyghem MC, Bihan H, Delemer B, Raverot G, Motte E, Philippon M, Morange I, Conte-Devolx B, Quinquis L, Martinie M, Vezzosi D, Le Bras M, Baudry C, Christin-Maitre S, Goichot B, Chanson P, Young J, Chabre O, Tabarin A, Bertherat J, Brue T (2014) Ketoconazole in Cushing\u2019s disease: is it worth a try? J Clin Endocrinol Metab 99:1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2013-3628","journal-title":"J Clin Endocrinol Metab"},{"key":"397_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/17446651.2020.1802243","volume":"15","author":"C Capatina","year":"2020","unstructured":"Capatina C, Hinojosa-Amaya JM, Poiana C, Fleseriu M (2020) Management of patients with persistent or recurrent Cushing\u2019s disease after initial pituitary surgery. Expert Rev Endocrinol Metab 15:321\u2013339. https:\/\/doi.org\/10.1080\/17446651.2020.1802243","journal-title":"Expert Rev Endocrinol Metab"},{"key":"397_CR32","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely A-J, de Herder WW, Hofland LJ, Lamberts SW (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N Engl J Med 362:1846\u20131848. https:\/\/doi.org\/10.1056\/NEJMc1000094","journal-title":"N Engl J Med"},{"key":"397_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","volume":"13","author":"L Vilar","year":"2010","unstructured":"Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura e Silva L, Agra R, Pontes L, Montenegro L, Albuquerque JL, Canadas V (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease. Pituitary 13:123\u2013129. https:\/\/doi.org\/10.1007\/s11102-009-0209-8","journal-title":"Pituitary"},{"key":"397_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","volume":"17","author":"M Barbot","year":"2014","unstructured":"Barbot M, Albiger N, Ceccato F, Zilio M, Frigo AC, Denaro L, Mantero F, Scaroni C (2014) Combination therapy for Cushing\u2019s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? Pituitary 17:109\u2013117. https:\/\/doi.org\/10.1007\/s11102-013-0475-3","journal-title":"Pituitary"},{"key":"397_CR35","doi-asserted-by":"publisher","first-page":"EDM190002","DOI":"10.1530\/EDM-19-0002","volume":"2019","author":"L Lawrence","year":"2019","unstructured":"Lawrence L, Zhang P, Choi H, Ahmad U, Arrossi V, Purysko A, Makin V (2019) A unique case of ectopic Cushing\u2019s syndrome from a thymic neuroendocrine carcinoma. Endocrinol Diabetes Metab Case Rep 2019:EDM190002. https:\/\/doi.org\/10.1530\/EDM-19-0002","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"397_CR36","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1530\/EJE-09-0098","volume":"160","author":"F Castinetti","year":"2009","unstructured":"Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Pic\u00f3 A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B (2009) Merits and pitfalls of mifepristone in Cushing\u2019s syndrome. Eur J Endocrinol 160:1003\u20131010. https:\/\/doi.org\/10.1530\/EJE-09-0098","journal-title":"Eur J Endocrinol"},{"key":"397_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/js.2018-00269","volume":"3","author":"TB Carroll","year":"2019","unstructured":"Carroll TB, Peppard WJ, Herrmann DJ, Javorsky BR, Wang TS, Patel H, Zarnecki K, Findling JW (2019) Continuous etomidate infusion for the management of severe Cushing syndrome: validation of a standard protocol. J Endocr Soc 3:1\u201312. https:\/\/doi.org\/10.1210\/js.2018-00269","journal-title":"J Endocr Soc"},{"key":"397_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1530\/EJE-20-0380","volume":"183","author":"SM Constantinescu","year":"2020","unstructured":"Constantinescu SM, Driessens N, Lefebvre A, Furnica RM, Corvilain B, Maiter D (2020) Etomidate infusion at low doses is an effective and safe treatment for severe Cushing\u2019s syndrome outside intensive care. Eur J Endocrinol 183:161\u2013167. https:\/\/doi.org\/10.1530\/EJE-20-0380","journal-title":"Eur J Endocrinol"},{"key":"397_CR39","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1210\/jcem-70-5-1426","volume":"70","author":"HM Schulte","year":"1990","unstructured":"Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B (1990) Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing\u2019s syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 70:1426\u20131430. https:\/\/doi.org\/10.1210\/jcem-70-5-1426","journal-title":"J Clin Endocrinol Metab"},{"key":"397_CR40","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12916-021-02080-8","volume":"19","author":"C Melau","year":"2021","unstructured":"Melau C, Riis ML, Nielsen JE, Perlman S, Lundvall L, Thuesen LL, Hare KJ, Hammerum MS, Mitchell RT, Frederiksen H, Juul A, J\u00f8rgensen A (2021) The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions. BMC Med 19:204. https:\/\/doi.org\/10.1186\/s12916-021-02080-8","journal-title":"BMC Med"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-022-00397-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-022-00397-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-022-00397-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T01:29:08Z","timestamp":1669858148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-022-00397-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["397"],"URL":"https:\/\/doi.org\/10.1007\/s42000-022-00397-4","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"assertion":[{"value":"6 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for the publication was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}